Prestige Consumer Healthcare Q2 revenue beats on acquisition boost 

Overview

• US consumer healthcare firm's Q2 revenue rose 22.7%, beating analyst expectations

• Adjusted diluted EPS for Q2 increased to $1.13 from $1.07 last year

• Company cut fiscal 2027 revenue and EPS outlook due to Clear Eyes® supply issues

Outlook

• Prestige Consumer Healthcare cuts FY27 revenue outlook to $1.28 bln-$1.29 bln

• Company lowers FY27 adjusted diluted EPS forecast to $4.48-$4.55

• Company expects Clear Eyes® supply constraints to weigh on second-half revenue

Result Drivers

• ACQUISITIONS - Revenue growth driven by contributions from Breathe Right and LaCorium acquisitions in both North American and International segments

• CLEAR EYES DECLINE - Organic revenue fell due to lower Clear Eyes sales and order timing headwinds

• HYDRALYTE GROWTH - International segment benefited from double-digit sales growth for Hydralyte

Company press release: ID:nGNX4r0hMH

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc. is $69.50, about 30.4% above its November 4 closing price of $53.28

• The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago

Reuters Recommended Reads

• Nov 4 - Evolus Q3 revenue rises 13% on toxin and HA gel growth

• Nov 4 - CVS beats Q3 revenue, profit estimates, outlook raised; to split into two

• Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)